Pharmacy-based predictors of non-persistence with and non-adherence to statin treatment among patients on oral diabetes medication in the Netherlands

被引:18
|
作者
Alfian, Sofa D. [1 ,2 ]
Worawutputtapong, Pawida [1 ]
Schuiling-Veninga, Catharina C. M. [1 ]
van der Schans, Jurjen [1 ]
Bos, Jens H. J. [1 ]
Hak, Eelko [1 ]
Denig, Petra [3 ]
机构
[1] Univ Groningen, Groningen Res Inst Pharm, Unit PharmacoTherapy Epidemiol & Econ, POB 196, NL-9700 AD Groningen, Netherlands
[2] Univ Padjadjaran, Dept Pharmacol & Clin Pharm, Fac Pharm, Jawa Barat, Indonesia
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands
关键词
Medication adherence; diabetes mellitus; hydroxymethylglutaryl-CoA reductase inhibitors; CHOLESTEROL RESPONSE; ADHERENCE; DISCONTINUATION; CARE; THERAPY;
D O I
10.1080/03007995.2017.1417242
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: To evaluate statin non-persistence and non-adherence as discrete processes in diabetes patients, and identify pharmacy-based predictors of these processes in the first year after statin initiation. Methods: We conducted a retrospective cohort study of statin initiators using a pharmacy database. Persistence and adherence were measured in the first, second and third year. Non-persistence was defined as a gap > 180 days. Non-adherence was calculated in persistent patients and defined as a medication possession ratio < 80%. Cox regression hazard ratios (HRs) and logistic regression odds ratios (ORs) were assessed for sociodemographic and medication-related factors as possible predictors. Results: Of 12,741 initiators, 20.0% were non-persistent in the first year, while 9.0% and 7.5% were non-persistent in the second and third years. Non-adherence in persistent patients increased from 13.4% in the first to 15.6% and 18.1% in the second and third years. Predictors of non-persistence were female gender (HR: 1.10; 95% CI: 1.01-1.19), older age (HR: 1.52; 95% CI: 1.31-1.75), primary prevention (HR: 1.10; 95% CI: 1.00-1.20), initiating on low dose (HR: 1.44; 95% CI: 1.07-1.94) or standard dose (HR: 1.56; 95% CI: 1.16-2.10), and no cardiovascular co-medication (HR: 1.19; 95% CI: 1.07-1.33), while patients with four or more other medications were more likely to be persistent. Age < 50 years (OR: 1.47; 95% CI: 1.22-1.77), low socioeconomic status (OR: 1.27; 95% CI: 1.12-1.45) and primary prevention (OR: 1.21; 95% CI: 1.07-1.38) were predictors of non-adherence, while females were more likely to be adherent (OR: 0.87; 95% CI: 0.77-0.98). Conclusion: Non-persistence was the foremost problem in the first year after statin initiation, while non-adherence in persistent patients increased in the second and third years. Pharmacy-based predictors of statin non-persistence were different from predictors of non-adherence among persistent patients.
引用
收藏
页码:1013 / 1019
页数:7
相关论文
共 50 条
  • [1] Pharmacy-based predictors of non-adherence, non-persistence, and re-initiation of antihypertensive drugs among patients on oral diabetes drugs in the Netherlands
    Alfian, Sofa Dewi
    Denig, Petra
    Coelho, Andre
    Hak, Eelko
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 425 - 425
  • [2] Predictors of Non-Adherence to and Non-Persistence with Statin Therapy Among Patients on Oral Diabetes Medication in the Netherlands: A Retrospective Inception Cohort Study
    Alfian, Sofa Dewi
    Worawutputtapong, Pawida
    Schuiling-Veninga, Catharina C. M.
    van der Schans, Jurjen
    Bos, Jens H.
    Hak, Eelko
    Denig, Petra
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 517 - 518
  • [3] Pharmacy-based predictors of nonadherence, non-persistence and reinitiation of antihypertensive drugs among patients on oral diabetes drugs in the Netherlands
    Alfian, Sofa D.
    Denig, Petra
    Coelho, Andre
    Hak, Eelko
    [J]. PLOS ONE, 2019, 14 (11):
  • [4] MEDICATION NON-ADHERENCE AND NON-PERSISTENCE IN A MANAGED CARE DIABETES MELLITUS POPULATION
    Nichol, M. B.
    Wu, J.
    Knight, T. K.
    Liberman, J. N.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A103 - A103
  • [5] PHARMACY-BASED INTERVENTIONS TO REDUCE PRIMARY MEDICATION NON-ADHERENCE
    Choudhry, Niteesh K.
    Fischer, Michael
    Bykov, Katsiaryna
    Brill, Gregory
    Bopp, Gregory
    Wurst, Aaron M.
    Shrank, William
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2013, 28 : S145 - S146
  • [6] Pharmacy-Based Interventions To Reduce Primary Medication Non-Adherence
    Fischer, Michael A.
    Bykov, Katsiaryna
    Choudhry, Niteesh K.
    Brill, Gregory
    Bopp, Gregory
    Wurst, Aaron M.
    Shrank, William H.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 421 - 421
  • [7] Systematic review: non-adherence and non-persistence in intravitreal treatment
    Christoph Ehlken
    Focke Ziemssen
    Nicole Eter
    Ines Lanzl
    Hakan Kaymak
    Albrecht Lommatzsch
    Alexander K. Schuster
    [J]. Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258 : 2077 - 2090
  • [8] Systematic review: non-adherence and non-persistence in intravitreal treatment
    Ehlken, Christoph
    Ziemssen, Focke
    Eter, Nicole
    Lanzl, Ines
    Kaymak, Hakan
    Lommatzsch, Albrecht
    Schuster, Alexander K.
    [J]. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2020, 258 (10) : 2077 - 2090
  • [9] Predictors of medication non-adherence for vasculitis patients
    Delesha M. Carpenter
    Susan L. Hogan
    Robert F. DeVellis
    [J]. Clinical Rheumatology, 2013, 32 : 649 - 657
  • [10] Predictors of medication non-adherence for vasculitis patients
    Carpenter, Delesha M.
    Hogan, Susan L.
    DeVellis, Robert F.
    [J]. CLINICAL RHEUMATOLOGY, 2013, 32 (05) : 649 - 657